LX1001

Mar 02, 2022 LEXEO Therapeutics Announces Positive Initial Data from Ongoing Phase 1/2 Clinical Trial of AAV-based Gene Therapy Candidate LX1001 in Patients with Alzheimer’s Disease

Apr 20, 2021 LEXEO Therapeutics Announces FDA Fast Track Designation Granted to LX1001